NASDAQ:AURA Aura Biosciences (AURA) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free AURA Stock Alerts $7.51 +0.04 (+0.54%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$7.26▼$7.7350-Day Range$6.95▼$7.8952-Week Range$5.99▼$13.02Volume87,097 shsAverage Volume201,021 shsMarket Capitalization$372.05 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aura Biosciences alerts: Email Address Aura Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside179.6% Upside$21.00 Price TargetShort InterestBearish6.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.80) to ($1.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.50 out of 5 starsMedical Sector659th out of 904 stocksBiological Products, Except Diagnostic Industry106th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingAura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAura Biosciences has received no research coverage in the past 90 days.Read more about Aura Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.92% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in Aura Biosciences has recently decreased by 2.17%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAura Biosciences does not currently pay a dividend.Dividend GrowthAura Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AURA. Previous Next 2.5 News and Social Media Coverage News SentimentAura Biosciences has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aura Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AURA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aura Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Aura Biosciences is held by insiders.Percentage Held by Institutions96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aura Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aura Biosciences are expected to grow in the coming year, from ($1.80) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aura Biosciences is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aura Biosciences is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAura Biosciences has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aura Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before… Click here now to download the free Precious Metals Buying Guide. About Aura Biosciences Stock (NASDAQ:AURA)Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More AURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AURA Stock News HeadlinesMay 30, 2024 | globenewswire.comAura Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)May 23, 2024 | globenewswire.comAura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024May 10, 2024 | finance.yahoo.comAura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial OverviewMay 9, 2024 | investorplace.comAURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024May 9, 2024 | globenewswire.comAura Biosciences Reports First Quarter 2024 Financial Results and Business HighlightsMay 8, 2024 | finance.yahoo.comOne Aura Biosciences Insider Raised Stake By 232% In Previous YearMay 8, 2024 | globenewswire.comAura Biosciences to Participate in Upcoming Investor ConferencesApril 20, 2024 | msn.comFF16 Ultima Abilities And How To Unlock Them In The Rising TideMarch 29, 2024 | msn.com3 Best Stocks to Buy Now, 3/29/2024, According to Top AnalystsMarch 29, 2024 | markets.businessinsider.comAura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial HealthMarch 28, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Molina Healthcare (MOH) and Aura Biosciences Inc (AURA)March 28, 2024 | finance.yahoo.comWe're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn RateMarch 27, 2024 | investorplace.comAURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023March 27, 2024 | benzinga.comRecap: Aura Biosciences Q4 EarningsMarch 27, 2024 | businesswire.comAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 13, 2024 | msn.comNational Assembly Counters Doctors Petition on SHIFFebruary 26, 2024 | businesswire.comAura Biosciences to Participate in Upcoming Investor ConferencesFebruary 23, 2024 | benzinga.comAura Biosciences Stock (NASDAQ:AURA), Short Interest ReportJanuary 7, 2024 | finance.yahoo.comOwning 48% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),January 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)December 11, 2023 | finance.yahoo.comWall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a BetDecember 9, 2023 | benzinga.comAura Biosciences Stock (NASDAQ:AURA), Analyst Ratings, Price Targets, PredictionsDecember 7, 2023 | finance.yahoo.comAura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaNovember 23, 2023 | finance.yahoo.comWall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to TradeSee More Headlines Receive AURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/08/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AURA CUSIPN/A CIK1501796 Webwww.aurabiosciences.com Phone617-500-8864FaxN/AEmployees88Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$23.00 Low Stock Price Target$19.00 Potential Upside/Downside+179.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.79% Return on Assets-36.47% Debt Debt-to-Equity RatioN/A Current Ratio21.97 Quick Ratio21.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.58 per share Price / Book1.64Miscellaneous Outstanding Shares49,540,000Free Float46,868,000Market Cap$372.05 million OptionableNot Optionable Beta0.37 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Elisabet de los Pinos Ph.D. (Age 51)Founder, CEO, President & Director Comp: $795.3kMs. Julie B. Feder (Age 54)CFO, Secretary & Treasurer Comp: $505.45kMr. Patrick NealonSenior Vice President of Clinical Development OperationsDr. Bruce Brown M.D.Senior VP & Therapeutic Area Head of Urologic OncologyDr. Anthony Daniels M.D.Therapeutic Area Head of Ocular OncologyDr. Richard Mountfield Ph.D.Senior Vice President of Regulatory Affairs & QualityMore ExecutivesKey CompetitorsUroGen PharmaNASDAQ:URGNInventivaNASDAQ:IVAUrovant SciencesNASDAQ:UROVProQR TherapeuticsNASDAQ:PRQRKaryopharm TherapeuticsNASDAQ:KPTIView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 18,354 shares on 5/20/2024Ownership: 0.037%Levin Capital Strategies L.P.Bought 11,200 shares on 5/16/2024Ownership: 0.224%Price T Rowe Associates Inc. MDSold 64,152 shares on 5/15/2024Ownership: 1.202%American International Group Inc.Bought 3,782 shares on 5/14/2024Ownership: 0.035%EntryPoint Capital LLCSold 14,262 shares on 5/14/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions AURA Stock Analysis - Frequently Asked Questions Should I buy or sell Aura Biosciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AURA shares. View AURA analyst ratings or view top-rated stocks. What is Aura Biosciences' stock price target for 2024? 3 Wall Street analysts have issued twelve-month price targets for Aura Biosciences' shares. Their AURA share price targets range from $19.00 to $23.00. On average, they anticipate the company's share price to reach $21.00 in the next year. This suggests a possible upside of 179.6% from the stock's current price. View analysts price targets for AURA or view top-rated stocks among Wall Street analysts. How have AURA shares performed in 2024? Aura Biosciences' stock was trading at $8.86 on January 1st, 2024. Since then, AURA shares have decreased by 15.2% and is now trading at $7.51. View the best growth stocks for 2024 here. When is Aura Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our AURA earnings forecast. How were Aura Biosciences' earnings last quarter? Aura Biosciences, Inc. (NASDAQ:AURA) issued its earnings results on Thursday, May, 9th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.11. What ETFs hold Aura Biosciences' stock? ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR).AltShares Event-Driven ET (EVNT). When did Aura Biosciences IPO? Aura Biosciences (AURA) raised $81 million in an initial public offering on Friday, October 29th 2021. The company issued 5,400,000 shares at a price of $14.00-$16.00 per share. Who are Aura Biosciences' major shareholders? Aura Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.41%), Regency Capital Management Inc. DE (1.59%), Price T Rowe Associates Inc. MD (1.20%), Levin Capital Strategies L.P. (0.22%), Virtu Financial LLC (0.04%) and American International Group Inc. (0.04%). Insiders that own company stock include Cadmus Rich, David Michael Johnson, Julie B Feder, Los Pinos Elisabet De, Matrix Capital Management Comp and Rosch Mark De. View institutional ownership trends. How do I buy shares of Aura Biosciences? Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AURA) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.